Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Bone Marrow
Hematopoietic and lymphoid neoplasms usually are diagnosed using a combination of routine morphologic assessment by light microscopy, histochemical stains, and immunophenotyping. Immunophenotyping is a method that detects expression of various cell surface (membrane) markers known as cluster designation (CD) antigens. Quantitative expression of these markers, coupled with light microscopic morphology, histochemical staining, immunochemical staining, chromosome analysis, and gene rearrangement studies is crucial to diagnosis and treatment selection. Immunophenotyping using selected leukemia and lymphoma-related CD antibodies in the flow cytometry method is generally considered the most important tool in the diagnosis and classification of leukemia and lymphoma. Other commonly used non-CD antibody markers include glycophorin A, HLA-DR, immunoglobulin (Ig), MPO (myeloperoxidase), and TdT (terminal deoxynucleotidyl transferase).
Since there are many different types of leukemia and lymphoma and each displays a unique combination of CD antigen expression, a specific type of leukemia/lymphoma can be diagnosed based on the pattern of CD antigen expression determined by the flow cytometry method. In any given sample, a panel is made of several CD and other markers that are analyzed and reported by flow cytometry. This is combined with light microscopic morphology, histochemical and immunohistochemical special stains (if needed), and chromosome analysis. Multicolor analysis and gating on selected cell populations is performed by software using the flow cytometry data to determine if an abnormal population of cells is present, and if so, what its CD antigen profile is. Results for each leukemia and/or lymphoma panel are incorporated into an interpretive report generated for each specimen analyzed. Results of flow cytometry analysis are usually correlated with morphology of the specimen. Following consultation with the referring physician, additional markers may be included for difficult and unusual cases if necessary.
Flow cytometry ("flow") can also be used for non-neoplastic applications. These include assessing the presence and quantity of fetal red blood cells in the maternal circulation, enumerating T4 and T8 lymphocytes in HIV patients, quantifying CD55 and CD59 to evaluate for paroxysmal nocturnal hemoglobinuria, quantifying DNA content to assess for a neoplastic cell population, assessing for antibody bound to red blood cells, neutrophils and platelets, and blood typing in the blood bank for previously transfused patients.
- Detection of abnormal lymphoid populations
- Differentiating reactive from malignant (clonal) lymphoid populations
- Differential diagnosis of leukemia and lymphoma
- Disease management and therapeutic monitoring
- Detection of relapse and therapy change
Abnormal phenotype profile present in:
- Acute myeloid leukemias
- Acute lymphoblastic leukemias
- B- and T-cell non-Hodgkin lymphomas
- Plasma cell myeloma
Markers expressed mainly in:
- Hematopoietic precursors: HLA-DR, TdT, CD34
- B cells: CD19, CD20, CD22, CD24, CD10, CD79, Immunoglobulin heavy chains and light chains
- T cells: CD3, CD7, CD5, CD2, CD4, CD8
- Myeloid cells: MPO, CD13, CD33, CD11, CD117
- Markers that suggest megakaryocytic differentiation: CD41, CD42, CD61
- Erythroid differentiation: glycophorin, hemoglobin A
- Monocytic differentiation: CD14, CD15, CD64, CD68
- NK cells: CD16, CD56
- Hairy cell leukemia: CD103
Normal phenotype markers (Negative for abnormal tumor marker profile). Results for each leukemia and/or lymphoma panel are followed with an interpretative report generated for each specimen analyzed.
Morphology, Flow Cytometry.
Whole blood, Yellow top (ACD solution B), 10 cc. ACD (solution A), Heparin or EDTA acceptable, 10 cc.
- Ambient 96 hrs
- Refrigerated less than 96 hrs.
- If cytogenetics are needed, submit a separate specimen.
Bone Marrow, Yellow top (ACD solution B), 10 cc. ACD (solution A), Heparin or EDTA acceptable, 1 - 5 cc.
- Ambient 96 hrs
- Refrigerated less than 96 hrs.
If cytogenetics are needed, submit a separate specimen.
Lymph Node Biopsy or Other Tissue Biopsy
Submit several small (1 - 2 mm) pieces of representative tissue in RPMI or Tissue Transport Media. Not more than 5 pieces as a rule. Serous effusion fluid: 5 mL. CSF: 1 mL.
- Blood. 2011 Nov 29. [PMID: 22128143]
- Arch Pathol Lab Med. 2004;128:1004. [PMID: 15335254]
- Arch Pathol Lab Med. 2006 Dec;130(12):1850-8. [PMID: 17149963]
- Clin Chem. 1999 Oct;45(10):1708-17. [PMID: 10508115]
- WHO Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press (2001).